Search citation statements

Order By: Relevance
Select...
3
2
0
7
0

Year Published

1995
1995
2008
2008

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

0
7
0
Order By: Relevance
“…Although the protein carrier-peptide epitope conjugates have been successfully applied in many cases to prepare potent antigens or immunogens, some crucial disadvantages may prevent their application in human vaccines: (i) immune response to the carrier and the peptide-carrier linkage, (ii) alteration of the peptide epitope biological properties and "active" conformation, and (iii) the peptide epitope, which represents only a small portion of the total protein carrierpeptide epitope conjugate, may result in a minor fraction of specific antibodies [7,11,17,21,22]. To overcome these shortcomings arising from protein carriers, artificial carriers appeared in the literature the last decades, which are presented below.…”
Section: Protein Carriersmentioning
See 1 more Smart Citation
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 14 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 100,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…Although the protein carrier-peptide epitope conjugates have been successfully applied in many cases to prepare potent antigens or immunogens, some crucial disadvantages may prevent their application in human vaccines: (i) immune response to the carrier and the peptide-carrier linkage, (ii) alteration of the peptide epitope biological properties and "active" conformation, and (iii) the peptide epitope, which represents only a small portion of the total protein carrierpeptide epitope conjugate, may result in a minor fraction of specific antibodies [7,11,17,21,22]. To overcome these shortcomings arising from protein carriers, artificial carriers appeared in the literature the last decades, which are presented below.…”
Section: Protein Carriersmentioning
“…KLH is more likely to precipitate during cross-linking, because of its large size, and this can make handling KLH difficult in some cases. BSA is very soluble, but often is a good immunogen in its own right, whereas MSA or RSA may be used when the antibody response to the carrier molecule must be kept to a minimum [11,[16][17][18][19][20].…”
Section: Protein Carriersmentioning
“…The use of large carrier proteins for the construction of conjugate vaccines has, however, some disadvantages: A strong immune response against the carrier protein may result in suppression of carbohydrate-specific antibody production. [5,6] Alternatively, the large protein might contain immunosuppressive epitopes, [7][8][9] which can reduce the effectiveness of the vaccine. In addition, conjugation chemistry is often difficult to control leading to glycoproteins with ambiguities in structure and composition, which may affect the reproducibility of an immune response.…”
Section: Introductionmentioning
“…On the other hand, drawbacks in the use of artificial carriers may originate from steric hindrances due to the close proximity of the antigenic peptides or to the type of the linkage between the carrier and epitope. 16,17 We herein report on the use of a peptide based on the H-Asp 110 -Lys-Ile-Asp-Trp-Arg-Glu-Ser-Gly-Tyr-Val-Thr-GluVal 123 -OH (Fas14p) sequence of F. gigantica cathepsin L-cysteine proteinase 18,19 in fasciolosis immunodiagnosis and prevention. According to Cornelissen et al 5 peptides of sequences 103-122 and 110-129 were verified to be the major immunodominant epitopes of cathepsin-L 1 .…”
Section: Introductionmentioning